Ideas

GREENWOOD VILLAGE, Co and New York, NY — (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology. This trial is evaluating Nantheia™ A1002N5S for Opioid Sparing in the treatment of participants...

Read More

GREENWOOD VILLAGE, Colo. & LOS ANGELES , CA — (BUSINESS WIRE) - ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. The study will...

Read More

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for Opioid Use Disorder. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial. Pre-clinical and initial clinical studies show ANANDA’s...

Read More

GREENWOOD VILLAGE, Colo. & LOS ANGELES, CA (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharma company, today announced the commencement of a clinical trial to be done in collaboration with the Jane and Terry Semel Institute at David Geffen School of Medicine at UCLA, to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid...

Read More

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD...

Read More